2021 Updates on the EU Cosmetics Regulation
Substances classified as carcinogenic, mutagenic or toxic to reproduction (CMR) are, by default, not allowed in cosmetic products. Some substances have been recently classified as CMR according to the CLP Regulation, so the Commission decided to correct and amend the Annexes of the EU Cosmetics Regulation. There are 12 new ingredients prohibited in cosmetic product and new restrictions on the use of Titanium Dioxide and Salicylic Acid.

REGULATION (EC) NO 1223/2009 AND CMR SUBSTANCES

Regulation (EC) No 1272/2008, commonly called CLP Regulation, provides for a harmonized classification of substances as carcinogenic, mutagenic or toxic for reproduction (CMR) based on an opinion prepared by the Committee for Risk Assessment of the European Chemicals Agency (ECHA). Depending on the level of evidence of their CMR properties, substances are classified as CMR substances of category 1A, 1B or category 2.

By default, the use of substances classified as CMR (under the CLP Regulation) is banned according to Article 15 of the European Cosmetics Regulation (Regulation (EC) No 1223/2009). Nevertheless, a CMR substance may be used in cosmetic products, by way of exception, if specific conditions are fulfilled.

With the aim of implementing the prohibition of CMR substances, ensure legal compliance (particularly for economic operators and national competent authorities) and to ensure a high level of protection of human health, these compounds are included in Annex II (list of substances prohibited in cosmetics products) or Annex III (list of substances which cosmetic products must not contain except subject to the restrictions laid down) of the EU Cosmetics Regulation. A CMR substance may also be deleted from Annexes III to VI of the Regulation for these purposes.

CORRECTIONS AND AMENDMENTS TO THE ANNEXES

Certain substances have recently been classified as CMR, in accordance with CLP Regulation.

Last May, the European Commission published the Commission Regulation (EU) 2021/850, called “OMNIBUS III”, amending and correcting Annex II and amending Annexes III, IV and IV to Regulation (EC) No 1223/2009 on cosmetic products. The amendments to the Cosmetics Regulation apply from the same date of the Delegated Regulation and will come into force from 1 October 2021.

This means that the Annexes (II, III, IV and VI) of the EU Cosmetics Regulation will suffer modifications. Several ingredients will be included in Annex II, the list of substances prohibited in cosmetic products. A request for use of these ingredients in cosmetics by ways of exception was not submitted. The 12 substances which are going to be incorporated in the prohibition list are:

  • Cobalt (CAS number: 7440-48-4)
  • Metaldehyde (ISO); 2,4,6,8-tetramethyl- 1,3,5,7-tetraoxacyclooctane (CAS number: 108-62-3)
  • Methylmercuric chloride (CAS number: 115-09-3)
  • Benzo[rst]pentaphene (CAS number: 189-55-9)
  • Dibenzo[b,def]chrysene; dibenzo[a,h]pyrene (CAS number: 189-64-0)
  • Ethanol, 2,2′-iminobis-,N-(C13-15-branched and linear alkyl) derivs. (CAS number: 97925-95-6)
  • Cyflumetofen (ISO) (CAS number: 400882-07-7)
  • Diisohexyl phthalate (CAS number: 71850-09-4)
  • Halosulfuron-methyl (ISO) (CAS number: 100784-20-1)
  • 2-methylimidazole (CAS number: 693-98-1)
  • Metaflumizone (ISO) (CAS number: 139968-49-3 and CAS number: 852403-68-0)
  • Dibutylbis(pentane-2,4-dionato-O,O’)tin (CAS number: 22673-19-4)

Until now, according to the European Regulation (EC) No 1223/2009, Titanium Dioxide (see previous post) was included in the list of UV filters allowed in cosmetic products (Annex VI, nano and non-nano form) and in the list of colourants allowed in cosmetic products (Annex IV, when in compliance with certain criteria). The nano form of this ingredient is only allowed in ready for use preparations, except in applications that may lead to exposure of the end user’s lungs by inhalation and subject to the other conditions listed (entry 27a of Annex VI).

Recently, Titanium Dioxide in the powder form, containing 1% or more of particles with aerodynamic diameter of 10 µm or less, has been classified as ‘Carcinogen Category 2 (inhalation)’. Based on the 2020 SCCS (Scientific Committee on Consumer Safety) opinion, Titanium Dioxide in these conditions should not be authorized for use in applications that may give rise to inhalation exposure by the end user. This ingredient will be added to Annex III (restricted substances) and its use should only be allowed in face products in loose powder form and in hair aerosol spray products (as indicated in the SCCS conclusions). This restriction will be also added to the entries of Annex IV and Annex VI of this ingredient.

Other amendment to the Regulation (on Annex III) was made in regard to Salicylic Acid. Following the conclusions of the SCCS on this substance, the Commission concluded it was appropriate to authorize the use of Salicylic Acid for purposes other than preservative function, in body lotion, eye shadow, mascara, eyeliner, lipstick and roll-on deodorant in concentration of up to 0.5%. Previously, Salicylic Acid was only allowed as a preservative in such categories (up to concentration of 0.5%. The wording of the use conditions of this ingredient was modified for clarification purposes.

If you wish to get more information on these changes or other information related with cosmetic products Regulation in the European Union, do not hesitate to contact us at info@criticalcatalyst.com.

References:

  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
  2. Commission Regulation (EU) 2021/850 of 26 May 2021 amending and correcting Annex II and amending Annexes III, IV and VI to Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products.

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »